A Study to Evaluate the Efficacy and Safety of (D/C/F/TAF) Once Daily Fixed Dose Combination (FDC) Regimen in Newly Diagnosed, Antiretroviral Treatment-naive Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants Receiving Care in a Test and Treat Model of Care
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2017-07-24
- Last Posted Date
- 2020-09-25
- Lead Sponsor
- Janssen Scientific Affairs, LLC
- Target Recruit Count
- 109
- Registration Number
- NCT03227861
- Locations
- 🇺🇸
University of Miami, Miami, Florida, United States
🇺🇸Chatham County Health Department, Savannah, Georgia, United States
🇺🇸The Ruth M. Rothstein CORE Center, Chicago, Illinois, United States
Multiple Myeloma Patient Registry
Terminated
- Conditions
- First Posted Date
- 2017-06-08
- Last Posted Date
- 2018-08-22
- Lead Sponsor
- Janssen Scientific Affairs, LLC
- Target Recruit Count
- 85
- Registration Number
- NCT03180853
- Locations
- 🇺🇸
St. Bernard's Medical Center, Jonesboro, Arkansas, United States
🇺🇸Arizona Oncology Associates, PC - HAL, Phoenix, Arizona, United States
🇺🇸Genesis Cancer Center, Hot Springs, Arkansas, United States
A Study to Assess the Validation and Mapping of the Suicide Ideation and Behavior Assessment
- First Posted Date
- 2017-03-21
- Last Posted Date
- 2019-06-13
- Lead Sponsor
- Janssen Scientific Affairs, LLC
- Target Recruit Count
- 130
- Registration Number
- NCT03085108
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸CNS Network, Garden Grove, California, United States
🇺🇸Rutgers University, Piscataway, New Jersey, United States
Smartphones to Improve Rivaroxaban ADHEREnce in Atrial Fibrillation
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2016-12-19
- Last Posted Date
- 2018-10-26
- Lead Sponsor
- Janssen Scientific Affairs, LLC
- Target Recruit Count
- 139
- Registration Number
- NCT02996435
Study to Evaluate the Relative Bioavailability of Fixed-dose Combination Tablet Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) as a Whole Tablet, as a Split Tablet, and as Crushed Tablet in Healthy Adult Participants
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2016-12-07
- Last Posted Date
- 2017-04-04
- Lead Sponsor
- Janssen Scientific Affairs, LLC
- Target Recruit Count
- 30
- Registration Number
- NCT02984852
A Study to Evaluate Dara-CyBorD in Previously Untreated and Relapsed Subjects With Multiple Myeloma
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2016-11-01
- Last Posted Date
- 2021-10-08
- Lead Sponsor
- Janssen Scientific Affairs, LLC
- Target Recruit Count
- 101
- Registration Number
- NCT02951819
Comparative and Pragmatic Study of Golimumab Intravenous (IV) (Simponi Aria) Versus Infliximab (Remicade) in Rheumatoid Arthritis
Completed
- Conditions
- Interventions
- First Posted Date
- 2016-04-05
- Last Posted Date
- 2020-04-15
- Lead Sponsor
- Janssen Scientific Affairs, LLC
- Target Recruit Count
- 1279
- Registration Number
- NCT02728934
Real-World Study of Enzalutamide and Abiraterone Acetate (With Prednisone) Tolerability
- First Posted Date
- 2016-01-26
- Last Posted Date
- 2017-02-20
- Lead Sponsor
- Janssen Scientific Affairs, LLC
- Target Recruit Count
- 108
- Registration Number
- NCT02663193
Family Intervention in Recent Onset Schizophrenia Treatment (FIRST)
Completed
- Conditions
- Interventions
- Other: Caregiver psycho-education and skills trainingOther: Caregiver support available at the study siteDrug: Paliperidone palmitateDrug: ChlorpromazineDrug: DroperidolDrug: FluphenazineDrug: HaloperidolDrug: LoxapineDrug: PerphenazineDrug: PimozideDrug: ProchlorperazineDrug: ThiothixeneDrug: ThioridazineDrug: TrifluoperazineDrug: AripiprazoleDrug: AsenapineDrug: ClozapineDrug: IloperidoneDrug: OlanzapineDrug: PaliperidoneDrug: QuetiapineDrug: RisperidoneDrug: Ziprasidone
- First Posted Date
- 2015-11-09
- Last Posted Date
- 2019-01-23
- Lead Sponsor
- Janssen Scientific Affairs, LLC
- Target Recruit Count
- 296
- Registration Number
- NCT02600741
A Study of Rivaroxaban for Early Discharge of Low Risk Pulmonary Embolism From the Emergency Department
- First Posted Date
- 2015-10-22
- Last Posted Date
- 2018-06-01
- Lead Sponsor
- Janssen Scientific Affairs, LLC
- Target Recruit Count
- 114
- Registration Number
- NCT02584660
© Copyright 2024. All Rights Reserved by MedPath